top of page
Home
Calvine Healthcare
Calvine Sustainables
Equity Research
Basilea
Blog
Contact
Â
Use tab to navigate through the menu items.
All Posts
Search
Brian White
Dec 21, 2021
Basilea - Cresemba's China approval
Brian White
Dec 17, 2021
Basilea - A burgeoning oncology pipeline
Andrew Keith
Dec 14, 2021
Diurnal Group - Efmody 2022
Brian White
Dec 8, 2021
Basilea - Cresemba's momentum continues
Andrew Keith
Nov 19, 2021
Basilea - Can derazantinib be class-leading?
Brian White
Nov 16, 2021
Basilea - Oncology commitment
Brian White
Oct 11, 2021
Diurnal Group - making testosterone replacement therapy more convenient
Brian White
Oct 11, 2021
Basilea - Further data supports derazantinib's potential in gastric cancer
Andrew Keith
Sep 30, 2021
Diurnal Group - Smart Delivery
Brian White
Sep 30, 2021
Basilea - Cresemba moving towards approval in Japan
Brian White
Sep 17, 2021
Basilea - Derazantinib ESMO data deliver further support
Brian White
Sep 14, 2021
Diurnal Group - Full year results
Andrew Keith
Sep 1, 2021
Diurnal Group - Positive Efmody update
Brian White
Sep 1, 2021
Basilea - Firing on all fronts
Brian White
Aug 17, 2021
Basilea - A period of strong financial and pipeline performance
Andrew Keith
Aug 9, 2021
Diurnal Group - Efmody's commercialisation
Andrew Keith
Jul 29, 2021
Basilea - FDA orphan designation for lisavanbulin
Brian White
Jul 28, 2021
Diurnal Group trading update
Brian White
Jul 26, 2021
Basilea - Japanese NDA for Cresemba
Brian White
Jul 12, 2021
Diurnal Group - US FDA agrees an SPA for Chronocort
bottom of page
